PatientView ANNOUNCES THE RELEASE OF its latest report
September 24, 2011 - In this report ...
Senior executives of 50 major HIV/AIDS patient groups from around the world assess the quality of the HIV/AIDS R&D conducted by the 20
main pharmaceutical companies in the field. These assessments allow the companies to be ranked according to seven indicators of
effective R&D [more details below].
180 patient groups with an interest in HIV/AIDS also comment on their familiarity, and partnerships, with the 20 pharma companies and 32 biotech companies listed in this report.
The patient groups provide strategic guidance on how pharma can improve its R&D in the field of HIV/AIDS.
For a link to an animated presentation about the latest PatientView report, 'What pharma companies do patient groups think are best at HIV/AIDS R&D?', see end of press release
Gilead is the most effective company at HIV/AIDS R&D
Gilead ranks overall top for all 7 indicators of HIV R&D effectiveness. Abbott comes 2nd and Tibotec 3rd.
(The report publishes the rankings for all 20 pharma companies with an interest in HIV/AIDS R&D. Each of the 20 companies is judged on its
own merits even if they are related to other corporations eg ViiV Healthcare is ranked separately from GSK and Pfizer)
Familiarity of HIV/AIDS96% of organisations say that they are familiar with Pfizer. . Agouron, a subsidiary of Pfizer, ranks as the biotech company familiar to the largest percentage of HIV/AIDS patient groups; 26% of the organisations say that they are familiar with Agouron.
Abbott maintains the highest overall number of patient group partnerships-64. However, ViiV Healthcare ranks first when measured in terms the proportion of groups that are familiar with the company and which have partnerships with the corporation-43% of groups that are familiar with ViiV have partnerships with the company.
R&D companies to patient
The areas of HIV/AIDS in which all companies perform poorly are:
"Managing HIV/AIDS R&D to ensure that products carry lower prices".
"Providing compassionate use of HIV/AIDS drugs".
"Undertaking research among people representative of the patient population".
"Keeping clinical trials patients well informed".
"Searching for a cure for HIV/AIDS".
Strategic pointers: Some 100 patient groups advise the following:
Increase the availability of medicines: reduce the price of medication and testing; harmonise prices around theworld; and concentrate more on the needs of the poorer parts of the world and marginalised populations.
Consider specific priorities in R&D: reduce side-effects and drug interactions; follow other priority directions in R&D; share the results of R&D; and work towards finding a cure.
Emphasise collaboration: look towards collaborative efforts; become involved in partnerships and programmes (including those of NGOs); communicate more closely with people living with HIV/AIDS; emphasise corporate responsibility.
Improve drug adherence: produce more user-friendly medication; ensure that patient information is user-friendly; and consider the needs of specific elements of the population.
Change the conduct of clinical trials to consider the needs of specific parts of the patient population within clinical trials, and the post-trial needs of participants
Further details about the report, 'What do Patients Think of Pharma HIV/AIDS R&D?' (September 2011)
In June 2011, the United Nations issued a political declaration aimed at intensifying the efforts of researchers to find new ways to tackle
HIV/AIDS with affordable treatments. And in July 2011, the Geneva-based International AIDS Society (IAS) announced a global scientific
strategy, 'Towards an HIV Cure', that intends to define "scientific priorities which must be addressed by future research to tackle
HIV persistence in patients undergoing antiretroviral therapy. In light of the UN declaration and the IAS initiative,
PatientView decided to find out WHAT PATIENT GROUPS THINK OF INDUSTRY'S HIV/AIDS R&D, AND WHETHER IT COULD IMPROVE.
The seven indicators by which the HIV/AIDS patient groups measured the effectiveness of pharma company HIV/AIDS R&D
1. Being best at providing people with HIV/AIDS with 'special access' to drugs (after good results have been obtained in clinical trial, but
before the drugs have been approved by regulators).
2. Being best at managing R&D effectively (with the direct aim of ensuring newest medications are not so expensively priced).
3. Being best at providing compassionate use of HIV/AIDS drugs to people who would otherwise not be able to afford to pay for them.
4. Being best at tackling major clinical questions that people living with HIV/AIDS want answered about HIV/AIDS drugs (such as reducing
side-effects, or making drugs easier to take).
5. Being best at undertaking clinical research among people truly representative of the population of individuals who are living with
6. Being best at keeping patients in clinical trials well informed about the processes in which they are partaking.
7. Being most innovative in the search for a cure for HIV/AIDS.
Companies assessed in this report Abbott
Bristol Myers Squibb (BMS)
Johnson & Johnson
Merck & Co
Roche (Hoffmann-La Roche)
The 20 pharma companies (though some companies are related to one another, each was assessed by patient groups on individual merit):
The 32 biotech companies:
The patient groups participating in the study
180 patient groups with an interest in HIV/AIDS from 41 countries contributed opinions on their familiarity and partnership with
HIV/AIDS biotech and pharma companies. Senior executives from 50 of the 180 groups went on to assess the effectiveness of the
companies' HIV/AIDS R&D.
Link to animated presentation: http://bit.ly/mRtmYi
For more about PatientView research and reports http://patientview.posterous.com (blog)
Tel: 00 44 (0)1547 520 965
"Reproduced with permission - PatientView "